Rigicon Infla10® Three-Piece Inflatable Penile Prosthesis (ERASE ED)

Erectile Dysfunction Clinical Trial

Official title:

Evaluation of the Rigicon Infla10® Three-Piece Inflatable Penile Prosthesis for the Treatment of Patients With Erectile Dysfunction

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05574868
• Other study ID #: RGN-ED-IPP-202201
• Status: Recruiting
• Phase: N/A
• Start date: July 11, 2022
• Est. completion date: May 21, 2026

Study information

• Verified date: November 2023
• Source: Rigicon, Inc.
• Contact: Orhan Koca, MD
• Phone: +90 532 562 15 13
• Email: drorhankoca[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the long-term safety and efficacy of the use of the Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis in patients with erectile dysfunction. This study follows patients implanted with the Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis for up to 3 years after implantation.

This study will take approximately 6 months to enroll all subjects. (14 days, 1 month, 6 months, 12 months,18 months, 24 months, and 36 months, post-procedure. )

Subjects will be followed per protocol and institutional standard of care for ED and comorbidities.

Description:

Erectile dysfunction (ED) is a common male sexual dysfunction associated with a reduced quality of life for patients and their partners. Incidence of ED increases with age and is associated with depression, obesity, diabetes mellitus, hypertension, cardiovascular disease and benign prostatic hyperplasia. ED is diagnosed with symptoms of (1) inability to attain or sustain a penile erection during sexual activity and (2) a reduction of penile rigidity in >75% of sexual encounters during six months period. ED is estimated to affect approximately 52% of men in age of 40 to 70 years.It is projected in 2025, the worldwide ED prevalence of about 322 million. ED usually has organic causes, such as damage of arteries, smooth muscle and fibrous tissue. This resuls in impairment of blood flow to and from penis due to diabetes, renal disease, atherosclerosis and vascular disease.

Management of ED involves in life style modification, medical, surgical interventions, and possibly, in the future, tissue- engineering or cellular or gene therapy. Oral phosphodiesterase type 5 inhibitor (PDE5i), which works with sexual stimulation, is an effective medical therapy for ED with an excellent safety profile. Intracavernosal injection of or topical application vasoactive drug have also been studied. The first inflatable penile prosthesis was introduced in 1973 and current models of inflatable penile prostheses include the AMS 700 series, Coloplast Titan device and Zephyr ZSI device. A patient-activated inflatable penile prosthesis (IPP) provides patients a means to achieve dependable spontaneity for intercourse.

Rigicon has developed a three-piece inflatable penile prosthesis (IPP) (Infla10®) for the treatment of ED. This proposed study is to assess the safety and effectiveness of the Rigicon IPP in treating ED. Clinical literature and preclinical testing, including biocompatibility, device validation and verification, and animal studies support the safety and efficacy of this device for the intended therapy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 177
• Est. completion date: May 21, 2026
• Est. primary completion date: May 21, 2026
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 21 Years to 90 Years

Eligibility

Inclusion Criteria:

1. Male =21 years of age.

2. Diagnosed with erectile dysfunction (impotence).

3. Agree to receive Infla10® three-piece IPP as an ED treatment.

4. Willing to complete all protocol required follow-up visits and tests.

Exclusion Criteria:

1. Contraindication to general anesthesia.

2. Known allergy or sensitivity to product materials as indicated in the device labeling.

3. Previous penile prosthesis or prior enlargement surgeries

4. Diagnosed penile sensory neuropathy

5. Diagnosed with fibrotic disease, such as priapism, Peyronie's disease or Chordee.

6. Compromised immune system, such as systemic lupus erythematosus, discoid lupus, or scleroderma

7. Uncontrolled diabetes (FBS >300 on morning of surgery)

8. Bleeding disorder or coagulopathy that may in the judgment of the investigator preclude safe procedure.

9. Active urogenital infection or active skin infection in region of surgery or systemic infection at the time of assessment.

10. Clinically significant comorbidities or presence of unstable conditions (e.g. cardiovascular, lung, renal [serum creatinine > 2.0 mg/dl], hepatic, bleeding disorders, or metabolic impairment) that may confound the results of the study or in the judgment of the physician investigator preclude safe procedure.

11. Any cognitive disorder that interferes with or precludes direct and accurate communication with the study investigator regarding the study or affects the ability to complete the study questionnaires.

12. Lacking manual dexterity or mental abilities necessary to operate the device.

13. Expected life expectancy < two years.

14. Unwilling or unable to sign the Informed Consent.

15. Unwilling or unable to comply with the follow-up study requirements.

16. Currently participating in an investigational drug or another investigational device exemption (IDE) study.

Related Conditions & MeSH terms

• Erectile Dysfunction

Intervention

Device:
• Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis
Treatment: Erectile dysfunction

Locations

Country	Name	City	State
Turkey	SBU Diskapi Yildirim Beyazit Training and Research Hospital	Ankara
Turkey	Haydarpasa Numune Training and Research Hospital	Istanbul
Turkey	Kavacik Medistate Hospital	Istanbul

Sponsors (1)

Lead Sponsor	Collaborator
Rigicon, Inc.

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rigidity at 12 months	Physician measurement of the rigidity of the fully inflated device at 12 months post-implant	12 months
Primary	Survival at 12 months	Freedom from surgical revision at 12 months post-procedure	12 months
Secondary	Serious complications	Incidence of device or procedure-related serious complications	36 months